Keryx Biopharmaceuticals, Inc. (KERX) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. increased its position in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) by 5.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,198,269 shares of the biopharmaceutical company’s stock after purchasing an additional 349,521 shares during the quarter. Vanguard Group Inc. owned approximately 6.06% of Keryx Biopharmaceuticals worth $52,043,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its stake in shares of Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 590 shares during the period. Jane Street Group LLC purchased a new position in shares of Keryx Biopharmaceuticals in the 1st quarter valued at approximately $141,000. Legal & General Group Plc lifted its stake in shares of Keryx Biopharmaceuticals by 1.2% in the 1st quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 300 shares during the period. Stifel Financial Corp lifted its stake in shares of Keryx Biopharmaceuticals by 11.5% in the 1st quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 3,478 shares during the period. Finally, Lincoln Capital Corp lifted its stake in shares of Keryx Biopharmaceuticals by 20.5% in the 2nd quarter. Lincoln Capital Corp now owns 36,500 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 6,200 shares during the period. Institutional investors own 65.20% of the company’s stock.

Keryx Biopharmaceuticals, Inc. (KERX) opened at $6.37 on Friday. The company has a quick ratio of 5.16, a current ratio of 5.76 and a debt-to-equity ratio of 4.88.

KERX has been the subject of a number of recent research reports. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a research note on Wednesday, July 12th. BidaskClub cut Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Maxim Group reiterated a “buy” rating and set a $9.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Thursday, July 20th. Cowen and Company reiterated a “market perform” rating on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $7.00 price objective (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $7.48.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2017/11/04/keryx-biopharmaceuticals-inc-kerx-shares-bought-by-vanguard-group-inc.html.

Keryx Biopharmaceuticals Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX).

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

What are top analysts saying about Keryx Biopharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Keryx Biopharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit